Mukamel E, Servadio C
Institute of Urology, Beilinson Medical Centre, Petah Tiqva, Israel.
Br J Urol. 1994 Jul;74(1):44-6. doi: 10.1111/j.1464-410x.1994.tb16544.x.
To report tumour recurrence related to cessation of long-term therapy with thiotepa.
A group of 12 patients with low grade (I-II), low stage (TA-T1) transitional cell carcinoma of the bladder were included in the study. All patients had been treated with intravesical thiotepa for a period ranging from 24 to 71 months and none had had a recurrence for a period of between 15 and 51 months. After referral to this department all the patients were withdrawn from thiotepa therapy.
All the patients developed bladder tumours within 6 months of cessation of therapy. The recurrent tumours were grade II in 10 patients and grade III in two patients. Eight patients had stage TA and four had stage T1. All responded to bacille Calmette-Guérin therapy and none had tumour recurrence on follow up at 24 months.
Meticulous follow-up of patients is indicated soon after the cessation of long-term therapy with thiotepa.
报告与硫替派长期治疗中断相关的肿瘤复发情况。
本研究纳入了12例低级别(I-II级)、低分期(TA-T1期)膀胱移行细胞癌患者。所有患者均接受膀胱内注射硫替派治疗24至71个月,且在15至51个月内均未复发。转诊至本科室后,所有患者均停止硫替派治疗。
所有患者在停止治疗后6个月内均出现膀胱肿瘤。10例复发肿瘤为II级,2例为III级。8例患者为TA期,4例为T1期。所有患者对卡介苗治疗均有反应,且在24个月随访时均无肿瘤复发。
硫替派长期治疗停止后,应尽快对患者进行细致的随访。